206 related articles for article (PubMed ID: 31188522)
1. Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study.
Money D; Lee T; O'Brien C; Brophy J; Bitnun A; Kakkar F; Boucoiran I; Alimenti A; Vaudry W; Singer J; Sauve LJ;
BJOG; 2019 Oct; 126(11):1338-1345. PubMed ID: 31188522
[TBL] [Abstract][Full Text] [Related]
2. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.
Zash R; Holmes L; Diseko M; Jacobson DL; Brummel S; Mayondi G; Isaacson A; Davey S; Mabuta J; Mmalane M; Gaolathe T; Essex M; Lockman S; Makhema J; Shapiro RL
N Engl J Med; 2019 Aug; 381(9):827-840. PubMed ID: 31329379
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
Kintu K; Malaba TR; Nakibuka J; Papamichael C; Colbers A; Byrne K; Seden K; Hodel EM; Chen T; Twimukye A; Byamugisha J; Reynolds H; Watson V; Burger D; Wang D; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721
[TBL] [Abstract][Full Text] [Related]
4. Dolutegravir in pregnancy-effects on HIV-positive women and their infants.
Bornhede R; Soeria-Atmadja S; Westling K; Pettersson K; Navér L
Eur J Clin Microbiol Infect Dis; 2018 Mar; 37(3):495-500. PubMed ID: 29396773
[TBL] [Abstract][Full Text] [Related]
5. Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir.
Vannappagari V; Thorne C;
J Acquir Immune Defic Syndr; 2019 Aug; 81(4):371-378. PubMed ID: 30939532
[TBL] [Abstract][Full Text] [Related]
6. Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?
Chouchana L; Beeker N; Treluyer JM
J Acquir Immune Defic Syndr; 2019 Aug; 81(4):481-486. PubMed ID: 31021990
[TBL] [Abstract][Full Text] [Related]
7. Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure.
Jacobs TG; van Aerde KJ; Colbers A; Burger DM
Pediatr Infect Dis J; 2022 Feb; 41(2):131-132. PubMed ID: 35017453
[TBL] [Abstract][Full Text] [Related]
8. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
Dugdale CM; Ciaranello AL; Bekker LG; Stern ME; Myer L; Wood R; Sax PE; Abrams EJ; Freedberg KA; Walensky RP
Ann Intern Med; 2019 May; 170(9):614-625. PubMed ID: 30934067
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.
Nguyen B; Foisy MM; Hughes CA
Ann Pharmacother; 2019 Aug; 53(8):833-844. PubMed ID: 30739498
[No Abstract] [Full Text] [Related]
10. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
[TBL] [Abstract][Full Text] [Related]
11. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants.
Williams PL; Crain MJ; Yildirim C; Hazra R; Van Dyke RB; Rich K; Read JS; Stuard E; Rathore M; Mendez HA; Watts DH;
JAMA Pediatr; 2015 Jan; 169(1):48-55. PubMed ID: 25383770
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
[TBL] [Abstract][Full Text] [Related]
13. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study.
Pereira GFM; Kim A; Jalil EM; Fernandes Fonseca F; Shepherd BE; Veloso VG; Rick F; Ribeiro R; Pimenta MC; Beber A; Corrêa RG; Lima R; Maruri F; McGowan CC; Schwartz Benzaken A; Grinsztejn B; Castilho JL;
Lancet HIV; 2021 Jan; 8(1):e33-e41. PubMed ID: 33387477
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus.
Bollen P; Freriksen J; Konopnicki D; Weizsäcker K; Hidalgo Tenorio C; Moltó J; Taylor G; Alba-Alejandre I; van Crevel R; Colbers A; Burger D;
Clin Infect Dis; 2021 Jan; 72(1):121-127. PubMed ID: 32103260
[TBL] [Abstract][Full Text] [Related]
15. Antenatal and neonatal antiretroviral therapy in HIV-infected women and their infants: a review of safety issues.
Thorne C; Newell ML
Med Wieku Rozwoj; 2003; 7(4 Pt 1):425-36. PubMed ID: 15010553
[TBL] [Abstract][Full Text] [Related]
16. The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women.
Laker EAO; Arinaitwe A; Owarwo N; Onzia A; Nasasira B; Wailagala A; Kalule I; Anguzu G; Kiragga A; Seden K; Lwanga I; Castelnuovo B; Musomba R; Lamorde M
Drug Saf; 2020 Nov; 43(11):1133-1140. PubMed ID: 32926356
[TBL] [Abstract][Full Text] [Related]
17. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Gaolethe T; Petlo C; Lockman S; Holmes LB; Makhema J; Shapiro RL
Lancet Glob Health; 2018 Jul; 6(7):e804-e810. PubMed ID: 29880310
[TBL] [Abstract][Full Text] [Related]
18. Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects.
Mofenson LM; Pozniak AL; Wambui J; Raizes E; Ciaranello A; Clayden P; Ehrenkranz P; Fakoya A; Hill A; Khoo S; Mahaka I; Modi S; Moore C; Phillips A; Siberry G; Sikwese K; Thorne C; Watts HD; Doherty M; Ford NP
J Int AIDS Soc; 2019 Jul; 22(7):e25352. PubMed ID: 31298496
[TBL] [Abstract][Full Text] [Related]
19. Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication.
Watts DH; Huang S; Culnane M; Kaiser KA; Scheuerle A; Mofenson L; Stanley K; Newell ML; Mandelbrot L; Delfraissy JF; Cunningham CK
J Perinat Med; 2011 Mar; 39(2):163-70. PubMed ID: 21142844
[TBL] [Abstract][Full Text] [Related]
20. Brief Report: Surveillance of Congenital Anomalies After Exposure to Raltegravir or Elvitegravir During Pregnancy in the United Kingdom and Ireland, 2008-2018.
Rasi V; Cortina-Borja M; Peters H; Sconza R; Thorne C
J Acquir Immune Defic Syndr; 2019 Mar; 80(3):264-268. PubMed ID: 30531300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
